Unicycive Therapeutics (UNCY) Financials: Revenue & Earnings

UNCY price $3.67 +0.06 +1.52%

Ticker
UNCY
Price
$3.67
Change
+0.06 +1.52%
Market cap ?
$100.40M
P/E ?
-2.16
Forward P/E ?
2.60
Dividend yield ?
0.00%
Beta ?
1.82
Sector
Healthcare
Industry
Biotechnology

Financials

20182019202020212022202320242025
000095100067500000

Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.

Fair value

UNCY fair value $37.95. Price $3.67. Price is 90% below fair value.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Calculated with a 10-year free-cash-flow discount. Starting free cash flow 146.27K. Growth 20.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 12.00% (beta 1.8). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 27.39M. Net debt -29.00M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the stock's own 10-year median P/E, kept between 8 and 40. Fewer than five years of history uses the sector's typical P/E. Fair value is the average of the cash-flow value and the earnings value when both exist. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.

Model uncertainty high for this stock

Compare UNCY

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-11—-0.33—902.78K
2026-08-12-0.06-0.47—22.22M
2026-05-12-0.54-0.55—11.11M
2026-03-30-0.82-0.46—517.00K
2025-11-12-0.33-0.59—2.37M
2025-08-14-0.52-0.70——
2025-05-14-0.50-0.67——
2025-03-27-2.76-0.13—10.00M
2024-11-13-0.50-0.86—10.00M
2024-08-14-1.50-1.99——
2024-05-13-2.70-0.18——
2024-03-28-1.60-1.68——
2023-11-14-1.30-0.13——
2023-08-14-2.90-3.08——
2023-05-16-2.90-0.37675.00K400.00K
2023-03-31-3.50-0.26—400.00K
2022-11-14-0.37-0.28951.00K—
2022-08-15-2.40-0.23——
2022-05-12-2.40-0.17——
2022-03-31-1.70-0.14——
2021-11-11-3.70-1.10——
2021-08-16-0.13-0.11——
2021-03-31-0.11———
2020-12-31-0.06———
2020-09-30-0.08———
2020-06-30-0.04———
2020-03-31-0.02———

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-10-01Manning MeredithOther0——
2026-05-14Kenkare-Mitra SaraBuy47.94K——
2026-05-14Laumas SandeepBuy47.94K——
2026-05-14Gupta Shalabh K.Buy762.20K——
2026-05-14Kenkare-Mitra SaraBuy42.10K——
2026-05-14Kenkare-Mitra SaraBuy84.20K——
2026-05-14Jermasek DouglasBuy169.50K——
2026-05-14Gupta PramodBuy169.50K——
2026-05-14Townsend JohnBuy169.50K——
2026-05-14Laumas SandeepBuy42.10K——
2026-05-14Laumas SandeepBuy84.20K——
2025-08-25Aggarwal GauravBuy652.90K——
2025-08-25Aggarwal GauravSell3.20K$4.9015.68K
2025-07-28Aggarwal GauravBuy21.20K$4.7199.85K
2025-07-28Laumas SandeepBuy21.20K$4.7199.85K
2025-07-28Kenkare-Mitra SaraBuy21.20K$4.7199.85K
2025-07-28Gupta Shalabh K.Buy325.00K$4.711.53M
2025-07-28Townsend JohnBuy10.00K$4.7147.10K
2025-07-28Gupta PramodBuy90.00K$4.71423.90K
2025-07-28Jermasek DouglasBuy10.00K$4.7147.10K
2025-02-18Aggarwal GauravBuy1.40M——
2025-02-18Aggarwal GauravSell686$0.49336
2024-10-09Aggarwal GauravBuy5.50M$1,000.005.50B
2024-10-09Aggarwal GauravSell2.69K$0.491.32K
2024-08-12Townsend JohnBuy40.26K$0.3413.69K
2024-08-12Gupta PramodBuy81.75K$0.3427.80K
2024-08-12Jermasek DouglasBuy81.75K$0.3427.80K
2024-08-12Gupta Shalabh K.Buy232.87K$0.3479.18K
2024-04-15Townsend JohnBuy228.12K$1.14260.06K
2024-04-15Jermasek DouglasBuy463.25K$1.14528.11K
2024-04-15Gupta PramodBuy463.25K$1.14528.11K
2024-04-15Gupta Shalabh K.Buy1.32M$1.141.50M
2023-09-05Laumas SandeepBuy189.24K$0.76143.82K
2023-09-05Kenkare-Mitra SaraBuy180.00K$0.76136.80K
2023-09-05Ryan John LBuy112.15K$0.7685.23K
2023-09-05Aggarwal GauravBuy180.00K$0.76136.80K
2023-09-05Kenkare-Mitra SaraOther0——
2023-08-28Gupta PramodBuy1.35M$0.751.02M
2023-08-28Gupta Shalabh K.Buy4.68M$0.753.51M
2023-08-28Townsend JohnBuy570.33K$0.75427.75K
2023-08-28Jermasek DouglasBuy1.35M$0.751.02M
2023-07-11Aggarwal GauravBuy18.62M$0.7413.80M
2023-07-11Aggarwal GauravBuy13.43M——
2023-07-11Aggarwal GauravBuy12.80M$0.546.90M
2023-07-11Aggarwal GauravBuy11.64M$0.596.90M
2023-07-11Aggarwal GauravBuy3.47M——
2023-07-11Aggarwal GauravSell8.08K$0.493.96K
2023-07-11Jermasek DouglasBuy104.61K$0.4951.26K
2023-07-11Jermasek DouglasBuy115.28K$0.7485.30K
2023-07-11Jermasek DouglasBuy79.25K$0.5442.80K
2023-07-11Jermasek DouglasBuy72.05K$0.5942.51K
2023-07-11Jermasek DouglasSell50$0.4924
2023-07-11Gupta PramodBuy46.11K$0.7434.12K
2023-07-11Gupta PramodBuy41.84K$0.4920.50K
2023-07-11Gupta PramodBuy31.70K$0.5417.12K
2023-07-11Gupta PramodBuy28.82K$0.5917.00K
2023-07-11Gupta PramodSell20$0.4910
2023-07-11Gupta Shalabh K.Buy104.61K$0.4951.26K
2023-07-11Gupta Shalabh K.Buy115.28K$0.7485.30K
2023-07-11Gupta Shalabh K.Buy79.25K$0.5442.80K
2023-07-11Gupta Shalabh K.Buy72.05K$0.5942.51K
2023-07-11Gupta Shalabh K.Sell50$0.4924
2023-03-08Aggarwal GauravBuy8.08K$0.493.98K
2023-03-08Gupta Shalabh K.Buy50$0.4925
2023-03-08Gupta PramodBuy20$0.4910
2023-03-08Jermasek DouglasBuy50$0.4925
2023-03-08Aggarwal GauravOther0——
2022-11-21Townsend JohnBuy35.00K——
2022-11-21Jermasek DouglasBuy55.00K——
2022-11-21Gupta Shalabh K.Buy86.00K——
2022-11-21Gupta PramodBuy28.00K——
2022-11-18Jermasek DouglasSell100.00K$2.56256.00K
2022-11-18Jermasek DouglasSell0——
2022-07-15Schiller BrigitteOther0——
2022-07-15Schiller BrigitteBuy26.74K——
2022-05-16Schiller BrigitteBuy15.00K$0.8212.38K
2021-07-15Gupta Shalabh K.Buy116.28K$5.00581.39K
2021-07-15Gupta PramodBuy34.88K$5.00174.42K
2021-07-15Townsend JohnBuy18.61K$5.0093.03K
2021-07-12Ryan John LSell0——
2021-07-12Ryan John LSell11.63K$0.01116
2021-07-12Gupta Shalabh K.Sell0——
2021-07-12Gupta Shalabh K.Other0——
2021-07-12Gupta Shalabh K.Other0——
2021-07-12Gupta Shalabh K.Other0——
2021-07-12Gupta Shalabh K.Sell101.74K$0.011.02K
2021-07-12Schiller BrigitteOther0——
2021-07-12Laumas SandeepOther0——
2021-07-12Laumas SandeepSell0——
2021-07-12Laumas SandeepSell11.63K$0.01116
2021-07-12Gupta PramodSell58.14K$3.27190.12K
2021-07-12Gupta PramodSell23.26K$7.01163.02K
2021-07-12Townsend JohnSell23.26K$7.01163.02K

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 90, holders +33 vs prior quarter. Ownership 43.34%.

HolderSharesChangeChange %Value
BLACKROCK, INC.1.41M1.38M+3836.67%6.63M
NANTAHALA CAPITAL MANAGEMENT, LLC1.40M462.25K+49.22%6.57M
VANGUARD CAPITAL MANAGEMENT LLC1.07M260.05K+32.05%5.03M
OCTAGON CAPITAL ADVISORS LP1.00M00.00%4.69M
DIADEMA PARTNERS LP792.60K686.52K+647.15%3.72M
GEODE CAPITAL MANAGEMENT, LLC564.02K360.27K+176.83%2.65M
VIVO CAPITAL, LLC550.00K-1.24M-69.27%2.58M
MARSHALL WACE, LLP547.86K392.92K+253.60%2.57M
LOGOS GLOBAL MANAGEMENT LP473.56K00.00%2.22M
STATE STREET CORP450.16K370.13K+462.51%2.11M
CAPTION MANAGEMENT, LLC420.00K420.00KNew1.97M
DIAMETRIC CAPITAL, LP374.13K293.77K+365.56%1.75M
SUSQUEHANNA INTERNATIONAL GROUP, LLP334.80K260.20K+348.79%1.57M
J. GOLDMAN & CO LP327.35K327.35KNew1.54M
SUSQUEHANNA INTERNATIONAL GROUP, LLP314.80K240.20K+321.98%1.48M
DIADEMA PARTNERS LP303.68K197.59K+186.26%1.42M
MILLENNIUM MANAGEMENT LLC271.46K-1.13M-80.60%1.27M
DAUNTLESS INVESTMENT GROUP, LLC214.00K66.91K+45.49%1.00M
CITIGROUP INC182.65K182.65K+18265300.00%856.65K
NORTHERN TRUST CORP181.93K145.99K+406.25%853.25K
JANE STREET GROUP, LLC178.90K137.70K+334.22%839.04K
VANGUARD PORTFOLIO MANAGEMENT LLC169.20K169.20KNew793.53K
SUSQUEHANNA INTERNATIONAL GROUP, LLP160.04K85.44K+114.53%750.58K
JUMP FINANCIAL, LLC153.00K153.00KNew717.57K
VANGUARD FIDUCIARY TRUST CO148.97K47.89K+47.38%698.65K

Earnings and financials

Unicycive Therapeutics, Inc. (UNCY) trades at $3.67, with a market cap of $100.40M and a trailing P/E of -2.16. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.

Financials

20182019202020212022202320242025
000095100067500000

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Unicycive Therapeutics (UNCY) Financials: Revenue & Earnings

UNCY$3.67+0.06 +1.52%

$100.40M

Market Cap

-2.16

P/E

2.60

Forward P/E

—

Score

Price History